Innovent Biologics, Inc. (HKG:1801)
92.30
-1.55 (-1.65%)
Dec 3, 2025, 11:59 AM HKT
Innovent Biologics Employees
Innovent Biologics had 5,659 employees as of December 31, 2024. The number of employees increased by 787 or 16.15% compared to the previous year.
Employees
5,659
Change (1Y)
787
Growth (1Y)
16.15%
Revenue / Employee
2.02M HKD
Profits / Employee
200.45K HKD
Market Cap
160.84B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5,659 | 787 | 16.15% |
| Dec 31, 2023 | 4,872 | -422 | -7.97% |
| Dec 31, 2022 | 5,294 | -274 | -4.92% |
| Dec 31, 2021 | 5,568 | 2,289 | 69.81% |
| Dec 31, 2020 | 3,279 | 1,297 | 65.44% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sino Biopharmaceutical | 24,379 |
| CSPC Pharmaceutical Group | 21,400 |
| WuXi Biologics | 12,575 |
| BeOne Medicines AG | 11,000 |
| Hansoh Pharmaceutical Group Company | 8,989 |
| JD Health International | 3,564 |
| Akeso | 3,035 |
| WuXi XDC Cayman | 2,041 |
Innovent Biologics News
- 4 days ago - China's First Domestic IL-23p19 Monoclonal Antibody: Innovent's PECONDLE® (Picankibart Injection) Received NMPA Approval - PRNewsWire
- 9 days ago - Innovent Biologics Enters Hang Seng Index and Two Other Major Indices; Global Capital Markets Recognize Leading Innovator's Value - PRNewsWire
- 11 days ago - Innovent, first Chinese firm to market weight-loss drug, joins Hang Seng Index - South China Morning Post
- 13 days ago - Innovent Biologics' Mazdutide Phase 3 Trial In Obesity Achieves Primary & Key Secondary Endpoints - Nasdaq
- 13 days ago - Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints - PRNewsWire
- 23 days ago - Innovent and SanegeneBio Announce Phase 1 Clinical Data for IBI3016 Presented at American Heart Association (AHA) 2025 Annual Meeting - PRNewsWire
- 4 weeks ago - Multiple Research Results from Innovent's General Biomedicine Pipeline Showcased at 2025 ACR Annual Meeting - PRNewsWire
- 4 weeks ago - Innovent's License Deal Fails To Excite investors - Benzinga